U.S. Packaging Stock News

Molina Healthcare has recently become the subject of multiple securities class action lawsuits and shareholder investigations alleging failures to disclose material adverse information about its medical cost trend assumptions, premium rate misalignment, and 2025 financial guidance cuts. These legal actions highlight concerns not just about current earnings pressure, but also about governance, disclosure practices, and how reliably investors can assess Molina’s underlying medical cost...

If you are wondering whether Hims & Hers Health is still a smart buy after its huge run, or if the easy money has already been made, this breakdown will help you decide whether the current price still stacks up against the fundamentals. The stock has cooled off a bit in the last month, down 6.5%, but that follows a powerful 58.8% gain year to date and a massive 452.0% jump over 3 years that has completely changed how the market views the business. Recent headlines have focused on Hims & Hers...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

We note that the Atlas Lithium Corporation ( NASDAQ:ATLX ) Independent Director, Robert Roger Noriega, recently sold...

In early December 2025, Charles River Laboratories International, Inc. shared an upbeat business update at the Evercore 8th Annual Healthcare Conference in Coral Gables, highlighting ongoing improvements in its Discovery and Safety Assessment net book-to-bill ratio since the third quarter. This steady month-by-month strengthening in orders since mid-2025 offers investors a clearer read-through on underlying demand recovery in one of the company’s core segments. With management pointing to...

In recent weeks, Nu Holdings has seen positive earnings estimate revisions, an analyst upgrade to Outperform from Grupo Santander, and confirmation that its planned 2026 Brazilian banking license should not alter day‑to‑day operations or capital requirements. Together, these developments point to growing confidence in Nu’s core Latin American franchise and its ability to integrate tighter regulation without disrupting customers. We’ll now examine how this renewed analyst optimism around Nu’s...

Prologis (PLD) has quietly outpaced many peers this year, and that climb is starting to make investors ask a simple question: is the current price still reasonable given its fundamentals? See our latest analysis for Prologis. The recent pullback, with a 1 day share price return of negative 0.78 percent from 128.18 dollars, comes after a strong 90 day share price return of 12.78 percent and a solid 5 year total shareholder return of 51.44 percent. This suggests momentum is still broadly intact...

Most readers would already be aware that Lincoln Educational Services' (NASDAQ:LINC) stock increased significantly by...

PNC Financial Services Group (PNC) has quietly outperformed many big-bank peers over the past month, and that steady climb is getting investors to revisit where this regional heavyweight might be headed next. See our latest analysis for PNC Financial Services Group. That recent 8.37% 1 month share price return has helped PNC claw back from a softer quarter, and with a 5 year total shareholder return of 64.94 percent, the stock still looks like a steady compounder rather than a short term...

In early December 2025, American Bitcoin Corp., a Trump-linked Bitcoin miner, faced intense volatility after a lock-up expiration allowed early pre-merger investors to sell previously restricted shares, triggering heavy trading, multiple halts, and profit-taking amid a weak backdrop for crypto-related equities. Despite the turbulence and heightened scrutiny over its China-made mining rigs, company leaders emphasized their long-term commitment, continued Bitcoin accumulation, and a recent...

UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders have had their patience rewarded with a 26% share price jump in the...

Cigna Group (CI) has been drifting lower recently. That kind of slow slide often makes investors wonder if the market is overlooking a fundamentally solid healthcare business with consistent cash generation. See our latest analysis for Cigna Group. Over the past year, Cigna Group’s share price returns have been choppy, with a recent 7 day share price return of minus 3.57 percent and a 90 day share price return of minus 12.08 percent. However, the 5 year total shareholder return of 37.98...

Wondering if Capricor Therapeutics is still a smart buy after its huge run, or if you are late to the party? This breakdown will help you decide whether the current price actually makes sense. The stock has exploded recently, jumping about 375% over the last week and 308.4% over the past month, and is now sitting around $25.40 after years of strong gains. That kind of move has come alongside renewed investor focus on Capricor’s cell and exosome based therapies, including its work in rare...

Wondering if Intel at around $40.50 is still a bargain or if most of the upside has already been priced in? You are not the only one trying to figure out whether now is the moment to buy or wait. Over the last week Intel is up about 10.0%, adding to a 9.4% gain over the past month and a striking 100.3% return year to date. This has quickly changed how investors are thinking about both its upside and its risks. Much of this move has been driven by renewed optimism around Intel's foundry...

Lemonade, Inc. ( NYSE:LMND ) shares have continued their recent momentum with a 31% gain in the last month alone...

In recent months, SES AI Corporation has accelerated its push into next-generation lithium batteries by acquiring UZ Energy, lifting revenue guidance, and improving its financial results while publicly releasing its Molecular Universe AI platform to speed up battery material discovery. This combination of AI-driven innovation, broader energy storage ambitions, and early software commercialization signals an attempt to build a differentiated, higher-margin battery technology ecosystem. We’ll...

If you are wondering whether Apple is still a buy at current levels, you are not alone. This article is going to focus squarely on what the numbers say about its underlying value. Over the last year the stock is up 16.1%, with gains of 3.9% over the past month and 15.1% year to date. This continues a longer run that has seen Apple climb 100.4% in three years and 135.6% over five years. Recently, investors have been focused on Apple expanding its services ecosystem and deepening its push into...

In the second quarter, Mackenzie Financial Corp reduced its holdings in Entergy Corporation by very large %, selling 150,266 shares and retaining 100,807 shares in the utilities provider. Around the same time, Entergy Louisiana broke ground on two highly efficient natural gas-fired plants totaling about 1,500 megawatts, a build-out closely tied to Meta’s new data center and projected to save customers roughly US$650 million over 15 years while supporting growing regional power needs. We’ll...

In recent months, Flex introduced a new AI-focused data center infrastructure platform and disclosed collaborations with NVIDIA and LG Electronics to build modular, energy-efficient data center solutions, aiming to speed up deployments and lower implementation risks for customers. This push deeper into AI-driven data center hardware and integrated systems is reshaping Flex’s role from a traditional contract manufacturer to a higher-value, solution-oriented partner across global cloud and AI...

It is a pleasure to report that the Wrap Technologies, Inc. ( NASDAQ:WRAP ) is up 59% in the last quarter. But that...

TeraWulf recently accelerated its shift from green Bitcoin mining to AI-focused, vertically integrated data centers, underpinned by over US$7.70 billion in contracted revenue and a US$3.20 billion Google financial guarantee. Google’s move to lift its stake in TeraWulf to 14% and backstop key AI infrastructure contracts highlights a reshaped business model and risk profile. Next, we’ll examine how Google’s expanded 14% ownership and financial backing may alter TeraWulf’s investment narrative...

Key Insights Significant control over Immix Biopharma by retail investors implies that the general public has more...

Wondering whether Amcor at around $8.32 is a value opportunity or a value trap? This breakdown will walk through what the current price really implies. Despite a tough run over the last year with a -14.0% return and -11.0% year to date, the stock has shown some life recently, gaining 5.7% over the last month even after a -3.5% slip in the past week. That recent volatility is unfolding against a backdrop of ongoing packaging industry shifts, from sustainability regulations to changing...

Edwards Lifesciences recently held its Analyst/Investor Day, where management outlined current business performance, portfolio priorities, and long-term growth plans for its structural heart and critical care franchises. The event gave investors deeper insight into how upcoming transcatheter therapies and ongoing R&D spending could reshape the company’s future earnings profile and capital allocation. Next, we’ll examine how the Analyst/Investor Day commentary on transcatheter pipeline...